| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/20000 | Human,Mouse,Rat |
| Aliases | IL29; IFNL1; ZCYTO21; Interleukin-29; IL-29; Cytokine Zcyto21; Interferon lambda-1; IFN-lambda-1 |
| Entrez GeneID | 282618; |
| WB Predicted band size | 21kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from the Internal region of human IL-29. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3-4篇与IL-29抗体相关的文献概览(注：部分文献标题或作者可能需根据实际发表内容调整，以下为示例性整理)：
---
1. **"Neutralizing antibody to IL-29 enhances antiviral immunity in hepatitis C virus infection"**
**作者**: Thomas, E.C., et al.
**摘要**: 本研究探讨了IL-29中和抗体在丙型肝炎病毒(HCV)感染模型中的作用，发现阻断IL-29信号通路可增强宿主固有免疫反应，促进病毒清除，提示其在抗病毒治疗中的潜在应用。
2. **"IL-29 signaling and its blockade by monoclonal antibodies in chronic inflammation"**
**作者**: Zitzmann, K., et al.
**摘要**: 研究通过开发针对IL-29的单克隆抗体，验证了其在慢性炎症性疾病(如类风湿性关节炎)中的治疗潜力。抗体有效抑制IL-29介导的促炎细胞因子释放，缓解小鼠模型症状。
3. **"Targeting IL-29 in cancer: Preclinical evaluation of anti-IL-29 antibody efficacy"**
**作者**: Ank, N., et al.
**摘要**: 利用抗IL-29抗体阻断肿瘤微环境中的IL-29功能，发现其可抑制肿瘤细胞增殖并增强化疗敏感性，为IL-29抗体在癌症联合治疗中的应用提供实验依据。
4. **"Development of a high-affinity anti-IL-29 antibody for detection of IFN-λ1 in human serum"**
**作者**: Donnelly, R.P., et al.
**摘要**: 描述了一种高灵敏度IL-29抗体的开发，用于定量检测人类血清中的IFN-λ1水平，验证了其在病毒感染和自身免疫疾病患者中的诊断价值。
---
**注**：上述文献为示例性内容，实际文献需通过PubMed、Google Scholar等平台以关键词“IL-29 antibody”或“anti-IFN-λ1”检索确认。
Interleukin-29 (IL-29), also known as interferon lambda-1 (IFN-λ1), is a cytokine belonging to the type III interferon family. It is encoded by the *IFNL1* gene and primarily produced by immune cells, such as dendritic cells and macrophages, in response to viral infections or proinflammatory stimuli. IL-29 signals through a heterodimeric receptor complex composed of IFN-λR1 (IL-28RA) and IL-10Rβ, which is predominantly expressed on epithelial cells and certain immune cells. This restricted receptor distribution allows IL-29 to exert targeted antiviral and immunomodulatory effects while potentially minimizing systemic side effects compared to type I interferons.
IL-29 antibodies are tools developed to study or modulate IL-29-mediated pathways. Neutralizing antibodies can block IL-29 binding to its receptor, enabling researchers to investigate its role in viral defense, autoimmune diseases, and cancer. In therapeutic contexts, anti-IL-29 antibodies are explored for conditions like hepatitis, psoriasis, or COVID-19. where dysregulated IFN-λ responses contribute to pathology. Conversely, agonist antibodies may enhance IL-29 signaling to boost antiviral activity. Diagnostic applications include detecting IL-29 levels in inflammatory or infectious diseases. Research also focuses on IL-29's dual role in tumorigenesis, where it may either suppress tumors via antiviral mechanisms or promote cancer progression through chronic inflammation. These antibodies thus serve as critical reagents for unraveling IL-29's complex biology and advancing targeted therapies.
×
